Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.

Pin-Nan ChengLein-Ray MoChun-Ting ChenChi-Yi ChenChung-Feng HuangHsing-Tao KuoChing-Chu LoKuo-Chih TsengYi-Hsiang HuangChi-Ming TaiCheng-Yuan PengMing-Jong BairChien-Hung ChenMing-Lun YehChih-Lang LinChun-Yen LinPei-Lun LeeLee-Won ChongChao-Hung HungTe Sheng ChangJee-Fu HuangChi-Chieh YangJui-Ting HuChih-Wen LinChia-Chi WangWei-Wen SuTsai-Yuan HsiehChih-Lin LinWei-Lun TsaiTzong-Hsi LeeGuei-Ying ChenSzu-Jen WangChun-Chao ChangSheng-Shun YangWen-Chih WuChia-Sheng HuangKwok-Hsiung ChouChien-Neng KaoPei-Chien TsaiChen-Hua LiuMei-Hsuan LeeChien-Yu ChengMing-Chang TsaiChun-Jen LiuChia-Yen DaiHan-Chieh LinJia-Horng KaoWan-Long ChuangMing-Lung Yunull null

Published in: Infectious diseases and therapy (2021)

SOF/VEL was highly effective and well tolerated in Taiwanese patients, irrespective of viral genotype, liver disease severity, and comorbidities.

Keyphrases

hepatitis c virus infection
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
hepatitis c virus
sars cov
prognostic factors
peritoneal dialysis
cross sectional
patient reported outcomes